Recent Research Analysts’ Ratings Changes for Viridian Therapeutics (VRDN)

Several analysts have recently updated their ratings and price targets for Viridian Therapeutics (NASDAQ: VRDN):

• 5/6/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $34.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $32.00 price target on the stock.
• 4/21/2026 – Viridian Therapeutics had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Viridian Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Viridian Therapeutics had its price target lowered by Wedbush from $37.00 to $31.00. They now have an “outperform” rating on the stock.
• 4/7/2026 – Viridian Therapeutics had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Viridian Therapeutics had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by The Goldman Sachs Group, Inc. from $41.00 to $36.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by Wells Fargo & Company from $29.00 to $20.00. They now have an “equal weight” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by Wedbush from $44.00 to $37.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by HC Wainwright from $34.00 to $22.00. They now have a “buy” rating on the stock.
• 3/30/2026 – Viridian Therapeutics had its price target lowered by Needham & Company LLC from $42.00 to $32.00. They now have a “buy” rating on the stock.
• 3/11/2026 – Viridian Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $44.00 price target on the stock.

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.